FDA already gives a special monopole privilege after clinical trials. FDA want to encourage companies in doing clinical trails, including on drugs which has an expired patent.

Evergreening is companies seeking monopole privilege after that original patent protection and the FDA protection has expired. Nothing to do with clinical trials.